Aigul Brimova
Research Subjects
Aigul Brimova has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Daulet Berikbol
«UMIT» International Oncology Center for Tomotherapy
4 shared publications - Anastasia Ganina
National Scientific Medical Center, Astana 010009, Kazakhstan
3 shared publications - Dana Idrissova
«UMIT» International Oncology Center for Tomotherapy
2 shared publications - Yerzhan Shayakhmetov
«UMIT» International Oncology Center for Tomotherapy
2 shared publications - Abay Baigenzhin
National Scientific Medical Center, Astana 010009, Kazakhstan
1 shared publication - Ainoor Baissalbayeva
Research Management Department UMIT International Oncological Center of Tomotherapy Astana Kazakhstan
1 shared publication
Latest Publications
- Open Access
- 12 November 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 77 (3) , 72-79
EFFICIENCY OF TOMOTHERAPY IN THE TREATMENT OF LUNG CANCER IN MALES WITH CONCOMITANT CARDIOVASCULAR PATHOLOGY (EXPERIENCE OF THE “UMIT” INTERNATIONAL ONCOLOGY CENTER OF TOMOTHERAPY)
Relevance: Non-small cell lung cancer (NSCLC) is frequently diagnosed in men with associated myocardial pathologies. Radiation therapy is one of the treatment methods for NSCLC; however, in Kazakhstan, there are virtually no studies on the efficacy and safety of tomotherapy in cancer patients with cardiac pathologies. The study aimed to evaluate the clinical results of mono-tomotherapy in patients with NSCLC and concomitant cardiac pathologies at the International Oncology Center for Tomotherapy “UMIT” (Astana, Kazakhstan). Methods: The study included 201 men with NSCLC who underwent spiral mono-tomotherapy at UMIT between 2020 and 2024. Patients were divided into Group 1 (n=139) – patients without cardiac pathologies- and Group 2 (n=62) – patients with severe associated cardiac pathologies. The average course duration was 32 days, the average treatment duration was 15 minutes, OD, 5 days a week. Treatment efficacy was assessed 8-12 weeks after completion of the course using PET-CT and CT data. Results: Complete regression was more common in patients in Group 1, while disease progression was more common in patients in Group 2. Partial responses were more common in Group 1, and stabilization of the oncological process was more common in Group 2. In Group 2, the proportion of patients with positive dynamics was 49%; after accounting for the identified stabilization of the process, it was 84%. In Group 1, the one-year overall survival rate was 84%, and 74% for stages III and IV, respectively, with a median progression-free survival of 10.3 months. The two-year survival rate for stage III disease was 65%. In Group 2, the one-year overall survival rate was 76% and 63% for stages III and IV, respectively, with a median progression-free survival of 8.1 months and a two-year survival rate of 54% for stage III. No device malfunctions were observed in Group 2. Two patients undergoing coronary artery bypass grafting experienced decompensated heart failure requiring temporary hospitalization. Conclusion: Tomotherapy demonstrates high clinical efficacy in the treatment of NSCLC with severe comorbid cardiac disease, although overall survival and treatment efficacy were lower than in patients without cardiac disease. Our experience confirms the feasibility of a relatively safe treatment in such patients when a personalized approach, strict dosimetric control, and multidisciplinary monitoring are employed
- 12 November 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 77 (3) , 72-79
Open AccessEFFICIENCY OF TOMOTHERAPY IN THE TREATMENT OF LUNG CANCER IN MALES WITH CONCOMITANT CARDIOVASCULAR PATHOLOGY (EXPERIENCE OF THE “UMIT” INTERNATIONAL ONCOLOGY CENTER OF TOMOTHERAPY)
Relevance: Non-small cell lung cancer (NSCLC) is frequently diagnosed in men with associated myocardial pathologies. Radiation therapy is one of the treatment methods for NSCLC; however, in Kazakhstan, there are virtually no studies on the efficacy and safety of tomotherapy in cancer patients with cardiac pathologies. The study aimed to evaluate the clinical results of mono-tomotherapy in patients with NSCLC and concomitant cardiac pathologies at the International Oncology Center for Tomotherapy “UMIT” (Astana, Kazakhstan). Methods: The study included 201 men with NSCLC who underwent spiral mono-tomotherapy at UMIT between 2020 and 2024. Patients were divided into Group 1 (n=139) – patients without cardiac pathologies- and Group 2 (n=62) – patients with severe associated cardiac pathologies. The average course duration was 32 days, the average treatment duration was 15 minutes, OD, 5 days a week. Treatment efficacy was assessed 8-12 weeks after completion of the course using PET-CT and CT data. Results: Complete regression was more common in patients in Group 1, while disease progression was more common in patients in Group 2. Partial responses were more common in Group 1, and stabilization of the oncological process was more common in Group 2. In Group 2, the proportion of patients with positive dynamics was 49%; after accounting for the identified stabilization of the process, it was 84%. In Group 1, the one-year overall survival rate was 84%, and 74% for stages III and IV, respectively, with a median progression-free survival of 10.3 months. The two-year survival rate for stage III disease was 65%. In Group 2, the one-year overall survival rate was 76% and 63% for stages III and IV, respectively, with a median progression-free survival of 8.1 months and a two-year survival rate of 54% for stage III. No device malfunctions were observed in Group 2. Two patients undergoing coronary artery bypass grafting experienced decompensated heart failure requiring temporary hospitalization. Conclusion: Tomotherapy demonstrates high clinical efficacy in the treatment of NSCLC with severe comorbid cardiac disease, although overall survival and treatment efficacy were lower than in patients without cardiac disease. Our experience confirms the feasibility of a relatively safe treatment in such patients when a personalized approach, strict dosimetric control, and multidisciplinary monitoring are employed
- Open Access
- 12 November 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 77 (3) , 72-79
EFFICIENCY OF TOMOTHERAPY IN THE TREATMENT OF LUNG CANCER IN MALES WITH CONCOMITANT CARDIOVASCULAR PATHOLOGY (EXPERIENCE OF THE “UMIT” INTERNATIONAL ONCOLOGY CENTER OF TOMOTHERAPY)
Relevance: Non-small cell lung cancer (NSCLC) is frequently diagnosed in men with associated myocardial pathologies. Radiation therapy is one of the treatment methods for NSCLC; however, in Kazakhstan, there are virtually no studies on the efficacy and safety of tomotherapy in cancer patients with cardiac pathologies. The study aimed to evaluate the clinical results of mono-tomotherapy in patients with NSCLC and concomitant cardiac pathologies at the International Oncology Center for Tomotherapy “UMIT” (Astana, Kazakhstan). Methods: The study included 201 men with NSCLC who underwent spiral mono-tomotherapy at UMIT between 2020 and 2024. Patients were divided into Group 1 (n=139) – patients without cardiac pathologies- and Group 2 (n=62) – patients with severe associated cardiac pathologies. The average course duration was 32 days, the average treatment duration was 15 minutes, OD, 5 days a week. Treatment efficacy was assessed 8-12 weeks after completion of the course using PET-CT and CT data. Results: Complete regression was more common in patients in Group 1, while disease progression was more common in patients in Group 2. Partial responses were more common in Group 1, and stabilization of the oncological process was more common in Group 2. In Group 2, the proportion of patients with positive dynamics was 49%; after accounting for the identified stabilization of the process, it was 84%. In Group 1, the one-year overall survival rate was 84%, and 74% for stages III and IV, respectively, with a median progression-free survival of 10.3 months. The two-year survival rate for stage III disease was 65%. In Group 2, the one-year overall survival rate was 76% and 63% for stages III and IV, respectively, with a median progression-free survival of 8.1 months and a two-year survival rate of 54% for stage III. No device malfunctions were observed in Group 2. Two patients undergoing coronary artery bypass grafting experienced decompensated heart failure requiring temporary hospitalization. Conclusion: Tomotherapy demonstrates high clinical efficacy in the treatment of NSCLC with severe comorbid cardiac disease, although overall survival and treatment efficacy were lower than in patients without cardiac disease. Our experience confirms the feasibility of a relatively safe treatment in such patients when a personalized approach, strict dosimetric control, and multidisciplinary monitoring are employed
- 12 November 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 77 (3) , 72-79
Open AccessEFFICIENCY OF TOMOTHERAPY IN THE TREATMENT OF LUNG CANCER IN MALES WITH CONCOMITANT CARDIOVASCULAR PATHOLOGY (EXPERIENCE OF THE “UMIT” INTERNATIONAL ONCOLOGY CENTER OF TOMOTHERAPY)
Relevance: Non-small cell lung cancer (NSCLC) is frequently diagnosed in men with associated myocardial pathologies. Radiation therapy is one of the treatment methods for NSCLC; however, in Kazakhstan, there are virtually no studies on the efficacy and safety of tomotherapy in cancer patients with cardiac pathologies. The study aimed to evaluate the clinical results of mono-tomotherapy in patients with NSCLC and concomitant cardiac pathologies at the International Oncology Center for Tomotherapy “UMIT” (Astana, Kazakhstan). Methods: The study included 201 men with NSCLC who underwent spiral mono-tomotherapy at UMIT between 2020 and 2024. Patients were divided into Group 1 (n=139) – patients without cardiac pathologies- and Group 2 (n=62) – patients with severe associated cardiac pathologies. The average course duration was 32 days, the average treatment duration was 15 minutes, OD, 5 days a week. Treatment efficacy was assessed 8-12 weeks after completion of the course using PET-CT and CT data. Results: Complete regression was more common in patients in Group 1, while disease progression was more common in patients in Group 2. Partial responses were more common in Group 1, and stabilization of the oncological process was more common in Group 2. In Group 2, the proportion of patients with positive dynamics was 49%; after accounting for the identified stabilization of the process, it was 84%. In Group 1, the one-year overall survival rate was 84%, and 74% for stages III and IV, respectively, with a median progression-free survival of 10.3 months. The two-year survival rate for stage III disease was 65%. In Group 2, the one-year overall survival rate was 76% and 63% for stages III and IV, respectively, with a median progression-free survival of 8.1 months and a two-year survival rate of 54% for stage III. No device malfunctions were observed in Group 2. Two patients undergoing coronary artery bypass grafting experienced decompensated heart failure requiring temporary hospitalization. Conclusion: Tomotherapy demonstrates high clinical efficacy in the treatment of NSCLC with severe comorbid cardiac disease, although overall survival and treatment efficacy were lower than in patients without cardiac disease. Our experience confirms the feasibility of a relatively safe treatment in such patients when a personalized approach, strict dosimetric control, and multidisciplinary monitoring are employed
- 30 September 2025
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 14 (3)
Tumor Microenvironment as a Key Target for Immunotherapy in Lung Cancer Patients
Lung cancer with a five-year survival rate of less than 20% is currently one of the most common malignancies worldwide. Cell-based immunotherapy showed promising results over the past two decades, but some patients still experience disease progression. Numerous studies identified the critical role of the tumor microenvironment in tumor progression, immune evasion, and treatment response. The dynamic interplay between the tumor and its surrounding microenvironment significantly influences both tumor behavior and the immune response. One of the critical components of this interplay is how essential nutrients and structural support are involved in tumor growth per se and cancer pathophysiology in general. A comprehensive understanding of the underlying mechanisms and molecular players critical to the tumor microenvironment is crucial to optimize immunotherapy strategies. This review examines key therapeutic targets in lung cancer, uncovering the complex interactions within the tumor microenvironment to enhance the efficacy of immunotherapy.
- 30 September 2025
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 14 (3)
Tumor Microenvironment as a Key Target for Immunotherapy in Lung Cancer Patients
Lung cancer with a five-year survival rate of less than 20% is currently one of the most common malignancies worldwide. Cell-based immunotherapy showed promising results over the past two decades, but some patients still experience disease progression. Numerous studies identified the critical role of the tumor microenvironment in tumor progression, immune evasion, and treatment response. The dynamic interplay between the tumor and its surrounding microenvironment significantly influences both tumor behavior and the immune response. One of the critical components of this interplay is how essential nutrients and structural support are involved in tumor growth per se and cancer pathophysiology in general. A comprehensive understanding of the underlying mechanisms and molecular players critical to the tumor microenvironment is crucial to optimize immunotherapy strategies. This review examines key therapeutic targets in lung cancer, uncovering the complex interactions within the tumor microenvironment to enhance the efficacy of immunotherapy.
- Open Access
- 29 April 2024
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 25 (7) , e14367
Tomotherapy in synchronous and metachronous bilateral breast cancer: Clinical experience
Purpose of study: The objective of this research is to present our firsthand experience and provide up‐to‐date data for the further study of cases involving simultaneous breast irradiation using helical Tomotherapy, ©Accuray Inc.Methods: The radical treatment options for bilateral breast cancer are surgery, chemotherapy, and radiation therapy. Being that radiotherapy for bilateral breast cancer is challenging due to limitations in the geometry of modern radiotherapy equipment, helical Tomotherapy was chosen as an appropriate technique of irradiation. The retrospective review focused on the records of patients who underwent bilateral irradiation of the breast or chest wall and regional lymph nodes using helical Tomotherapy.Results: Only four patients with bilateral breast cancer completed a radiation therapy course in our center from 2018 to 2023. Two patients underwent radical mastectomy with lymph node dissection on both sides before irradiation. For the other two patients, radical mastectomy was done after neoadjuvant chemotherapy. Acute radiation toxicity scoring was based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Only mild adverse effects, such as general weakness and slight skin irritation below Grade 3, were observed, with no instances of skin swelling, dryness, or pigmentation noted. Evaluation of late complications revealed tissue fibrosis in the area of the internal mammary nodes and respiratory failure with various severity. Complications and deterioration in the cardiovascular system were not observed during the follow‐up period, which varied from 3 to 48 months.Conclusion: Our results show the efficacy of using helical Tomotherapy considering positive outcomes, being that three out of four patients are in remission with low acute toxicity and late complications. There are a small number of articles describing bilateral breast cancer treatment with helical Tomotherapy. On this occasion, our data could contribute to the studies of tolerant doses for organs at risk and improve the parameters of treatment plans for bilateral breast cancer. Since the small sample of patients with bilateral breast cancer limits the study, a larger cohort of patients is essential to obtain statistically reliable results.
- 29 April 2024
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 25 (7) , e14367
Open AccessTomotherapy in synchronous and metachronous bilateral breast cancer: Clinical experience
Purpose of study: The objective of this research is to present our firsthand experience and provide up‐to‐date data for the further study of cases involving simultaneous breast irradiation using helical Tomotherapy, ©Accuray Inc.Methods: The radical treatment options for bilateral breast cancer are surgery, chemotherapy, and radiation therapy. Being that radiotherapy for bilateral breast cancer is challenging due to limitations in the geometry of modern radiotherapy equipment, helical Tomotherapy was chosen as an appropriate technique of irradiation. The retrospective review focused on the records of patients who underwent bilateral irradiation of the breast or chest wall and regional lymph nodes using helical Tomotherapy.Results: Only four patients with bilateral breast cancer completed a radiation therapy course in our center from 2018 to 2023. Two patients underwent radical mastectomy with lymph node dissection on both sides before irradiation. For the other two patients, radical mastectomy was done after neoadjuvant chemotherapy. Acute radiation toxicity scoring was based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Only mild adverse effects, such as general weakness and slight skin irritation below Grade 3, were observed, with no instances of skin swelling, dryness, or pigmentation noted. Evaluation of late complications revealed tissue fibrosis in the area of the internal mammary nodes and respiratory failure with various severity. Complications and deterioration in the cardiovascular system were not observed during the follow‐up period, which varied from 3 to 48 months.Conclusion: Our results show the efficacy of using helical Tomotherapy considering positive outcomes, being that three out of four patients are in remission with low acute toxicity and late complications. There are a small number of articles describing bilateral breast cancer treatment with helical Tomotherapy. On this occasion, our data could contribute to the studies of tolerant doses for organs at risk and improve the parameters of treatment plans for bilateral breast cancer. Since the small sample of patients with bilateral breast cancer limits the study, a larger cohort of patients is essential to obtain statistically reliable results.